ASCO Data Springs More Biotech Leaks

 

ASCO is leaking again.

Important cancer research data that were supposed to remain confidential and under wraps until next month's annual meeting of the American Society of Clinical Oncology have, instead, been leaked to select investors this week.

The result is volatility in the trading of some biotech cancer stocks. ImClone Systems (IMCL) fell 6% Tuesday and dropped another $1.48, or 3.6%, to $39.85 on Wednesday because an ASCO research abstract that detailed results from a study of Erbitux in colon cancer made its way onto Wall Street trading desks.

I made two phone calls Wednesday morning and was able to obtain specific data contained in the Erbitux abstract, which comes from the so-called Crystal study and was not supposed to be made public until the ASCO meeting, which starts June 1.

ASCO rules forbid me from revealing the Erbitux data, but needless to say, the stock's reaction tells you the data are disappointing from an investor perspective.

Chatter about ASCO abstract data is also responsible for moving the stocks of Genentech(DNA), Regeneron Pharmaceuticals(REGN) and Onyx Pharmaceuticals (ONXX), from what I can tell.

Do you think ASCO's policy of selective disclosure is fair?
Answer Here

For longtime followers of the big ASCO cancer meeting, this story of selective disclosure of market-moving drug data -- and the volatility it causes in the trading of biotech cancer stocks -- is a sad refrain. It seems to happen every year, and the blame can largely be laid at the doorstep of ASCO.

TheStreet Premium Services    For Personal Service: 877-471-2967

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
New: ETF Profits
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Doug Kass
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,801.23 1,342.64 2,903.88 19.69
Oil *
117.67
DOWN
89.23
DOWN
9.31
DOWN
23.35
DOWN
0.78
10 Yr
1.97%
SPDR Gold
167.14
-0.69%
-0.69%
-0.80%
-3.81%
Data delayed 20 minutes

Top Stories and Tools

Brokerage Partners

After the Bell

Before the Bell

Booyah! Newsletter

ETF Daily

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet